|By Business Wire||
|January 12, 2017 08:30 AM EST|
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Celgene Corporation has expanded its adoption of the Medidata Clinical Cloud® to include Medidata’s suite of strategic monitoring tools and data analytics solutions. Building on Celgene’s selection of Medidata as its enterprise technology partner in 2016, the global biopharmaceutical company is now implementing additional Medidata capabilities and machine learning tools to optimize clinical research processes, improve patient outcomes and drive value-based, personalized healthcare.
Leveraging the scale, agility and value provided by Medidata’s end-to-end clinical trial platform, Celgene is instituting processes to standardize data, effectively allocate trial resources and create consistency that will enable the seamless integration of information across its R&D programs worldwide. The addition of Medidata Centralized Statistical Analytics (CSA), Medidata TSDV and Medidata Coder® will further embed the Medidata Clinical Cloud within Celgene’s clinical development organization, providing its clinical teams with immediate insight into study site performance and data quality, and the tools to reduce coding cycle times. Using Medidata’s platform and analytics solutions more broadly will also help Celgene minimize risk, quickly apply corrective actions to manage issues and reach pivotal milestones sooner, ultimately speeding up trial timelines and reducing costs.
“Celgene is creating new pathways for collaboration and innovation across healthcare, enabling a faster and more flexible approach to R&D, and Medidata is proud to be a strategic partner in that effort,” said Glen de Vries, Medidata’s president. “Our cloud technology and advanced, data-driven analytics are helping Celgene—and a rapidly growing list of life sciences companies worldwide—derive insights to better understand disease, develop targeted therapies and make precision medicine a reality, accelerating hope for patients with some of the most difficult-to-treat illnesses.”
An integral part of Medidata’s cloud platform, CSA integrates patient data from different sources and provides a comprehensive data visualization tool for each subject participating in a clinical trial. The advanced, machine-learning algorithms in CSA enable clinical trial sponsors to uncover complex patterns in clinical trial data, rapidly detect statistical anomalies and identify data quality issues. CSA also provides end-to-end visibility, facilitating collaboration across study teams and helping researchers focus resources where they are needed most.
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@Celgene expands its use of the @Medidata platform, leveraging #riskbasedmonitoring & #machinelearning tools: http://ow.ly/B9zV307UCb3 #tech
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 800 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.
Jan. 20, 2017 04:45 PM EST Reads: 1,065
Jan. 20, 2017 03:00 PM EST Reads: 1,635
Jan. 20, 2017 02:30 PM EST Reads: 1,113
Jan. 20, 2017 02:15 PM EST Reads: 583
Jan. 20, 2017 01:30 PM EST Reads: 5,232
Jan. 20, 2017 01:30 PM EST Reads: 3,588
Jan. 20, 2017 01:30 PM EST Reads: 5,726
Jan. 20, 2017 01:00 PM EST Reads: 2,573
Jan. 20, 2017 12:30 PM EST Reads: 4,345
Jan. 20, 2017 12:30 PM EST Reads: 1,647
Jan. 20, 2017 12:30 PM EST Reads: 3,184
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and E...
Jan. 20, 2017 12:15 PM EST Reads: 5,833
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
Jan. 20, 2017 11:30 AM EST Reads: 760
WebRTC sits at the intersection between VoIP and the Web. As such, it poses some interesting challenges for those developing services on top of it, but also for those who need to test and monitor these services. In his session at WebRTC Summit, Tsahi Levent-Levi, co-founder of testRTC, reviewed the various challenges posed by WebRTC when it comes to testing and monitoring and on ways to overcome them.
Jan. 20, 2017 10:45 AM EST Reads: 6,086
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
Jan. 20, 2017 10:45 AM EST Reads: 3,701